MedTrace Logo

RadioPathomics Artificial Intelligence Model to Predict nCRT Response in Locally Advanced Rectal Cancer

NCT04271657 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-05-06

No results posted yet for this study

Summary

In this study, investigators utilize a radiopathomics integrated Artificial Intelligence (AI) supportive system to predict tumor response to neoadjuvant chemoradiotherapy (nCRT) before its administration for patients with locally advanced rectal cancer (LARC). By the system, whether the participants achieve the pathologic complete response (pCR) will be identified based on the radiopathomics features extracted from the pre-nCRT Magnetic Resonance Imaging (MRI) and biopsy images. The predictive power to discriminate the pCR individuals from non-pCR patients, will be validated in this multicenter, prospective clinical study.

Conditions

Sponsors & Collaborators

  • The Third Affiliated Hospital of Kunming Medical College.

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xinjuan Fan, MD, PhD · Sixth Affiliated Hospital, Sun Yat-sen University

  • Xiangbo Wan, MD, PhD · Sixth Affiliated Hospital, Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-10
Primary Completion
2020-11-09
Completion
2020-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04271657 on ClinicalTrials.gov